Can a Ohio resident get peptides by telehealth?
ORC 4743.09 (enacted by House Bill 122 of the 134th General Assembly, effective March 23, 2022) lets licensed health care professionals provide telehealth services, including initial and annual visits, using synchronous or asynchronous technology when the standard of care for an in-person visit is satisfied. The State Medical Board's rule OAC 4731-37-01 applies this to physicians and physician assistants, holds telehealth to the in-person standard of care, permits synchronous or asynchronous communication technology if that standard can be met for the patient's condition, and allows non-controlled prescription drugs to be prescribed through telehealth under the rule's requirements. The prescriber must hold an Ohio license. None of the peptides in this database are controlled substances. [2] [3]
How does the Ohio pharmacy board treat compounding?
| Board | State of Ohio Board of Pharmacy |
|---|---|
| Eligible substances | Follows the federal 503A framework |
The Board of Pharmacy licenses pharmacists and terminal distributors of dangerous drugs (which includes pharmacies) under ORC chapter 4729 and regulates pharmacy compounding through OAC chapter 4729:7-2 and prescriber compounding through OAC chapter 4729:7-3. On July 17, 2025 the Board issued GLP-1 compounding guidance with FAQs for licensees. It states that pharmacy and prescriber compounding of copies of tirzepatide ended February 18, 2025 and of semaglutide ended April 22, 2025; that retatrutide and cagrilintide cannot be used in compounding under federal and state law, with any inventory to be disposed of immediately; that research use only products may never be used for compounding; and that pharmacies, clinics, and outsourcing facilities in Ohio must buy all active ingredients from Ohio-licensed drug distributors. Ohio has no state bulks list beyond these positions; peptide eligibility follows the federal 503A framework. ORC 4729.54 directs the Board to license terminal distributors whether located within or outside Ohio, and OAC 4729:5-8-02 sets licensure requirements for nonresident pharmacies, including proof of a valid home-state license and the most recent inspection report. Starting February 1, 2027, amended OAC 4729:5-2-01 requires the responsible person on an Ohio terminal distributor license held by a clinic or med spa to work at least 8 hours a month at the licensed location or make a documented quarterly on-site visit (Board of Pharmacy guidance updated September 10, 2026). [1] [4] [5] [6] [7] [8] [14]
Can you get compounded GLP-1s in Ohio?
Compounded semaglutide and tirzepatide are limited to the federal exception for documented patient specific needs because the FDA shortage allowances ended in 2025, and the Ohio Board of Pharmacy's July 2025 GLP-1 FAQs reinforce that copies of the approved products are not routinely compoundable in Ohio. Ohio's asynchronous telehealth rule makes app-based prescribing lawful, so the main constraint for Ohio patients is the pharmacy side. [3] [4] [11]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path in Ohio?
Verified access options
Prescriber licensed in Ohio, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in Ohio. Asynchronous (questionnaire or messaging) prescribing is permitted when it meets the standard of care.
Pharmacy licensed or registered with the State of Ohio Board of Pharmacy
Check the dispensing pharmacy against the board's license lookup before paying, including out-of-state mail-order pharmacies.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Find a provider in Ohio
Is it legal to buy research peptides in Ohio?
ORC chapter 4729 restricts the sale and distribution of dangerous drugs to licensed pharmacies, distributors, and prescribers, and the Board reminds licensees to verify that sellers are licensed. Board guidance for prescriber clinics and medical spas (updated December 8, 2025) says any drug labeled for research purposes only is unlawful for a clinic or med spa to possess, even with patient consent, and must be disposed of immediately, with patients advised to stop using it. [1] [5] [12] [13]
Peptide-specific notes for Ohio
| Peptide | Note |
|---|---|
| Semaglutide | Available branded by prescription, including through synchronous or asynchronous telehealth under ORC 4743.09. The Ohio Board of Pharmacy's July 2025 GLP-1 FAQs and the end of the federal grace period on April 22, 2025 leave compounded semaglutide limited to documented patient specific needs. [2] [4] [11] |
| Tirzepatide | Available branded by prescription. Compounded tirzepatide is limited to the federal patient specific exception since February 18, 2025, and the Ohio Board's GLP-1 FAQs address it directly. [4] [11] |
| Retatrutide | Investigational and not FDA approved. The Ohio Board of Pharmacy's July 17, 2025 GLP-1 guidance states that retatrutide cannot be used in compounding under federal and state law and that licensees found compounding, selling, or administering it may face discipline, including summary suspension. [4] [11] |
Compare: Semaglutide vs retatrutide, Semaglutide vs tirzepatide, Tirzepatide vs retatrutide.
Frequently asked questions
Can I get a GLP-1 prescription in Ohio through an asynchronous telehealth app?
Yes, if the prescriber holds an Ohio license and the in-person standard of care can be met. ORC 4743.09 and OAC 4731-37-01 allow synchronous or asynchronous technology, including for initial visits, and non-controlled drugs like semaglutide may be prescribed through telehealth. [2] [3]
What does the Ohio Board of Pharmacy say about compounded GLP-1s?
In July 2025 the Board published GLP-1 compounding FAQs for licensees explaining how state and federal law apply after the FDA shortages ended. They treat copies of approved semaglutide and tirzepatide as no longer routinely compoundable. [4]
Is compounded semaglutide or tirzepatide still available in Ohio?
Only in limited, patient specific cases. The federal shortage allowances ended in 2025, and the Ohio Board of Pharmacy's FAQs reinforce that compounded copies are not a routine option. [4] [11]
Can an Ohio pharmacy compound retatrutide or BPC-157?
Retatrutide is an investigational drug, and the Ohio Board of Pharmacy's July 2025 GLP-1 guidance states that it cannot be used in compounding under federal and state law. BPC-157 is not yet on the final 503A bulks list, so compounding it carries regulatory risk, and Category 2 peptides cannot be compounded. [4] [9] [10]
How do I check that a pharmacy is licensed to serve Ohio?
Search the Ohio eLicense system for the pharmacy's terminal distributor license from the State of Ohio Board of Pharmacy. Sellers without an Ohio license are not lawful sources of prescription drugs in Ohio. [1] [5]
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.
- [1]State of Ohio Board of Pharmacy
- [2]Ohio Revised Code 4743.09, Telehealth services
- [3]Ohio Administrative Code 4731-37-01, Telehealth (State Medical Board of Ohio)
- [4]State of Ohio Board of Pharmacy: Compounding of GLP-1 drug products in Ohio, guidance and FAQs (issued July 17, 2025)
- [5]Ohio Revised Code chapter 4729, Pharmacists; dangerous drugs
- [6]Ohio Revised Code 4729.54, Terminal distributor licenses
- [7]Ohio Administrative Code 4729:5-8-02, Non-resident pharmacies: licensure
- [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
- [10]FDA: Pharmacy Compounding Advisory CommitteeFDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 27). Are peptides legal in Ohio?. https://peptideagent.ai/legal/ohio- HTML link
<a href="https://peptideagent.ai/legal/ohio">Are peptides legal in Ohio?</a>, PeptideAgent, updated September 27, 2026.